ASX Announcement

15 December 2021

TGA Registration Update

AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") advises that it has received feedback from the Therapeutic Goods Administration ("TGA") on its EuGeni Reader and SARS CoV- 2 Ag Rapid Diagnostic Test (RDT)[1] submission.

The TGA have completed a preliminary review and have requested that AnteoTech supply additional information and clarification in support of its submission.

The information requested relates to the performance of AnteoTech's RDT in relation to the detection of SARS-CoV-2 variants. In addition, the TGA has requested that AnteoTech provide plans for the monitoring of the emergence of new strains of SARS-CoV-2 and performance testing of the RDT against these strains, as well as other technical and performance elements.

AnteoTech is working with the TGA to provide the information as quickly as possible.

The Company will provide further updates as our submission progresses.

This announcement has been authorised for release by the Board.

For more information, please contact:

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

About AnteoTech - (ASX:ADO)

AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on Twitter (@AnteoTech_), LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive **Latest News** bulletin, our email alert service.

[1] The AnteoTech Antigen Rapid Diagnostic Test detects the SARS-CoV-2 active virus that causes the disease called COVID-19

AnteoTech Ltd
ACN 070 028 625
Unit 4, 26 Brandl Street, Eight Mile Plains, QLD, 4113
Australia

T +61 7 3219 0085
E investors@anteotech.com
anteotech.com